Sociedad Española de Terapia Génica y Celular
  • Home
  • About us
    • About us
    • History
    • Board Information
    • Awards
      • Award winners
    • Legal & bylaws
  • Events
    • Events
    • Sponsorship
    • Ask-the-expert
    • Current congress
    • e-School
    • e-Seminars
    • Previous Events
    • Upcoming events
    • Frequently asked questions
  • Networking & community
    • Networking & community
    • Gene and cell therapy community heatmap
    • Introduction to the Forum
    • Latest news
    • Non ESGCT events
    • Jobs & Courses
    • Blog
    • Newsletter archive
    • National Gene and cell therapy societies
  • Policies & advocacy
    • Policies & advocacy
    • Regulatory information
      • GMP Guidelines
    • EMA guidance
    • ESGCT statements
    • Useful links
  • Public & Patients
    • Public & Patients
    • Gene and cell therapy education
      • Covid 19 vaccines
      • Gene therapy 101
        • Cell therapy basics
        • Different approaches
        • Gene therapy basics
        • Vectors 101
    • Patients perspective
    • Sites of interest
    • What is gene therapy
  • Membership
    • Membership
    • Become a member
    • General Assembly of Members
    • Human Gene Therapy
    • Membership benefits
Home

This week in gene and cell therapy - 9 November 2018

Gene and cell therapy headlines 5 - 9 November


Gene therapy by injection into the spinal cord halts ALS

Gene therapy converts glia into functioning neurons in vivo

Majority of humans have immunity agains Streptococcus Cas9

Biodegradable scaffold enhances CNS stem cell therapy in mice

Account login

Create a secure accountJoin
Forgotten your details?

Sponsors

Diamond

Platinum

Gold

Silver

Bronze

Copyright © 2022 Sociedad Española de Terapia Génica y Celular Member Area Terms and Conditions user account Privacy Policy Cookies Terms and Conditions membership purchase Terms and Conditions congress registration Terms and Conditions abstract submission Terms and Conditions user account RSS feed Join us Follow us